Severe clozapine poisoning – case presentation

Authors

  • Magdalena Majewska Samodzielny Publiczny Szpital Wojewódzki im. Jana Bożego w Lublinie Regionalny Ośrodek Toksykologii Klinicznej Author
  • Jarosław Szponar Samodzielny Publiczny Szpital Wojewódzki im. Jana Bożego w Lublinie Regionalny Ośrodek Toksykologii Klinicznej Author

Keywords:

clozapine poisoning, acute respiratory failure, lactic acidosis

Abstract

Clozapine is an antipsychotic drug, which belongs to the group of atypical antipsychotic agents for the treatment of schizophrenia. Clozapine is a very effective medicine, but because of the possibility of inducing severe side effects, clozapine should be recommended only for patients who do not respond to other treatments or do not tolerate other drugs. Case presentation: a young 29-year-old man was hospitalized in the Regional Centre of Clinical Toxicology in Lublin, because of suicidal overdose of dozens of clozapine pills. The patient was taking clozapine due to paranoid schizophrenia. At the time of admission to hospital the patient was in severe general condition and there was no logical contact with him. In the laboratory test we observed severe features of lactic acidosis, which could be typical for clozapine poisoning. In addition the patient developed acute respiratory failure and rhabdomyolysis. For the next 6 days, thepatient required intensive treatment and care, including periodic respiratory therapy. The patient was discharged from the hospital in good general condition after 13 days of treatment and he was referred to Neuropsychiatric Hospital in Lublin. The patient was diagnosed in the course of clozapine poisoning with: toxic coma, lactic acidosis, acute respiratory failure, pneumonia and rhabdomyolysis.

References

1. Demler T.L., Trigoboff E. Are clozapine blood dyscrasis associated with cocncomitant medications? Innv. Clin. Neurosci., 2011; 8(4): 35-41.

2. Davydov L., Botts S.R. Clozapine-induced hypersalivation, Ann. Pharmacother., 2000; 34(5): 662-665.

3. Calderon J., Rubin E., Sobota W. L. Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation:a preliminary report. Int. Clin. Psychopharmacol., 2000: 15(1):49-52

4. Bird A.M., Smith T.L., Walton A.E. Current treatment strategies for clozapine-induced sialorrhea. Ann. Pharmacoter., 2011; 45(5): 667-675.

5. Ekstrom J., Godoy T., Riva A. Clozapine: agonist and antagonist salivary secretory actions. J. Dent. Res., 2010; 89(3): 276-280.

6. Abdelmawla N. Clozapine and risk of pneumonia. Br. J. Psychiatry, 2009;194: 468-469.

7. Pillai L., Husainy S., Ramchandani K. Diabetic ketoacidosis associated with atypical antipsychotic drug, clozapine treatment: report of a case and review of literature. IJCCM, 2006;10(3): 193-196.

8. Koren W., Kresis Y., Duchowiczny K., Prince T., Sancovici S., Sidi Y., et al. Lactic acidosis and fatal myocardial infarction due to clozapine. Ann. Pharmacother., 1997; 31: 168-170.

9. Liamis G., Haralampos J., Elisaf M., Elisaf M. Pharmacologically Induced Metabolic Acidosis A Review. Drug Saf., 2010; 33(5): 371-391.

10. Macfarlane B., Davies S., Mannan K., Sarsam R., Pariente D., Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine induced hepatotoxicity. Gastroenterology, 1997; 112(5): 1707-1709.

11. Koren W., Koren E., Nacasch N., Ehrenfeld M., Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decrease calcium dependent potassium permeability of cell membranes. Clin. Neuropharmacol., 1998; 21(4): 262-264.

Downloads

Published

2011-11-24